title: Nicotine patch and paroxetine for smoking cessation.
abstract: Smokers (N = 224) were randomized to 1 of 3 groups: (a) transdermal system (TNS) + placebo; (b) TNS + paroxetine (20 mg); (c) TNS + paroxetine (40 mg). Assignment to treatment was double-blind. Nicotine patch (TNS) treatment was provided for 8 weeks; paroxetine or placebo was provided for 9 weeks. Abstinence rates at Weeks 4, 10, and 26 were as follows: (a) TNS + placebo: 45%, 36%, and 25%; (b) TNS + paroxetine (20 mg): 48%, 33%, and 21%; (c) TNS + paroxetine (40 mg): 57%, 39%, and 27%. The differences were not statistically significant. The combined treatment was more effective in reducing both craving and depression symptoms associated with smoking cessation. A subgroup analysis comparing compliant participants was also conducted. Abstinence rates at Weeks 4, 10, and 26 were as follows: (a) TNS + placebo: 46%, 35%, and 24%; (b) TNS + paroxetine (20 mg): 64%, 43%, and 33%; (c) TNS + paroxetine (40 mg): 74%, 51%, and 38%. The differences between paroxetine groups and placebo at Week 4 were statistically significant. Although paroxetine may add value to the current standard of care in excess of potential risk, more conclusive evidence is needed.
authors.affiliation: Stanford University School of Medicine, Palo Alto, California 94304-1885, USA. Killen@SCRDP.Stanford.EDU
authors.forename: J D
authors.initials: JD
authors.lastname: Killen
authors.forename: S P
authors.initials: SP
authors.lastname: Fortmann
authors.forename: A F
authors.initials: AF
authors.lastname: Schatzberg
authors.forename: C
authors.initials: C
authors.lastname: Hayward
authors.forename: L
authors.initials: L
authors.lastname: Sussman
authors.forename: M
authors.initials: M
authors.lastname: Rothman
authors.forename: L
authors.initials: L
authors.lastname: Strausberg
authors.forename: A
authors.initials: A
authors.lastname: Varady
mesh_terms: D000279:Administration, Cutaneous; D000328:Adult; D018687:Antidepressive Agents, Second-Generation / Q000627:therapeutic use*; D003863:Depression / Q000517:prevention & control; D004311:Double-Blind Method; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009538:Nicotine / Q000008:administration & dosage / Q000627:therapeutic use*; D018722:Nicotinic Agonists / Q000008:administration & dosage / Q000627:therapeutic use*; D017374:Paroxetine / Q000627:therapeutic use*; D010349:Patient Compliance; D016540:Smoking Cessation / Q000379:methods*; D013375:Substance Withdrawal Syndrome / Q000517:prevention & control; D014029:Tobacco Use Disorder / Q000188:drug therapy*; D016896:Treatment Outcome
chemical_list: D018687:Antidepressive Agents, Second-Generation; D018722:Nicotinic Agonists; D017374:Paroxetine; D009538:Nicotine